InvestorsHub Logo
Followers 22
Posts 1717
Boards Moderated 0
Alias Born 10/22/2013

Re: None

Tuesday, 08/19/2014 9:54:13 AM

Tuesday, August 19, 2014 9:54:13 AM

Post# of 30990
Interesting article regarding Eli Lilly pursuit of "autoimmune" drug market. Think there is not some interest in seeing RCPI progress stopped?

http://www.ibj.com/eli-lilly-making-renewed-push-in-biotech-field-where-it-once-pioneered/PARAMS/article/49069

For those that scoff at "mouse study results", found this exerpt from the artcle especially interesting.


""Roughly a year after Lilly halted its autoimmune research effort, researchers in Greece demonstrated for the first time that biotech proteins slowed the progression of rheumatoid arthritis in mice.

That breakthrough led to the first successful human trial of a biotech autoimmune drug, the results of which were announced in 1994 by Pennsylvania-based biotech firm Centocor. When Centocor’s drug proved effective in 19 of 25 patients, it knew it had something that worked.

That drug, launched in 1998 as Remicade, became the first of the new wave of autoimmune drugs.

“That was the big tipping point, the big ‘Aha!’ moment,” Bumol said of the work that led to Remicade.""

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.